Latest From Xerox Corp.
The reorganizations of pharmaceutical R&D organizations has failed to address fundamental issues that afflict R&D across several industries. Most of this shortfall can be attributed to a dearth of effective leadership within the C-suites of the drug industry.
The need to move forward outweighs some members’ objections to the final definition developed by the Patient-Centered Outcomes Research Institute’s Methodology Committee.
Time already spent on developing and refining the definition outweighs certain members’ objections to the final version developed by the Patient-Centered Outcomes Research Institute’s Methodology Committee.
Standing panel would review research grant applications for potential conflicts and advise the PCORI board. Transparency is stressed as a COI avoidance tool.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Xerox Corp.
- Senior Management
Paul Allaire, Pres. & CEO
David T. Kearns, Chmn.
- Contact Info
Phone: (203) 968-3000
800 Long Ridge Rd.
P.O. Box 1600 Stamford, CT 06904-
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.